DISC-0974 is under clinical development by Disc Medicine and currently in Phase II for Anemia in Chronic Kidney Disease (Renal Anemia). According to GlobalData, Phase II drugs for Anemia in Chronic Kidney Disease (Renal Anemia) have a 58% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DISC-0974’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DISC-0974 overview
DISC-0974 is under development for the treatment of chronic inflammation and anemia in chronic kidney disease, myelofibrosis, chronic idiopathic myelofibrosis (primary myelofibrosis), post-essential thrombocythemia myelofibrosis (post-et mf), post-polycythemia vera myelofibrosis (ppv-mf), anemia of myelofibrosis (MF) and anemia of inflammatory bowel disease (IBD). The drug candidate acts by targeting hemojuvelin. It is administered through intravenous and subcutaneous routes.
It was also under development for the treatment of iron refractory iron deficiency anemia (IRIDA), myeloproliferative disorders and anemia of chronic disease.
Disc Medicine overview
Disc Medicine is a clinical-stage biopharmaceutical company primarily that focuses on advancing the field of hematology through the development of innovative therapies. The company’s main activities involve the research and development of treatments for hematologic diseases, with a particular emphasis on red blood cell biology. Its pipeline products include bitopertin for the treatment of erythropoietic porphyria’s, including erythropoietic protoporphyria, X-linked protoporphyria and Diamond-Blackfan Anemia:, DISC-0974 for the treatment of anemia of myelofibrosis and and anemia of chronic kidney disease. Disc Medicine is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of DISC-0974’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
